India’s First Dengue Vaccine Qdenga Set for 2027 Launch After Dr Reddy’s Partners with Takeda

In a move that could reshape India’s fight against dengue, Dr Reddy’s Laboratories announced on Friday that it has signed a distribution agreement with Japan’s Takeda Pharmaceutical. The partnership means Takeda’s Qdenga – the nation’s very first dengue vaccine cleared by the regulator – will be rolled out across the country, with sales kicking off sometime in the first half of 2027.

The approval itself was a landmark. Earlier this year the Indian drug regulator gave the green light to Qdenga for both children and adults, making it the only dengue vaccine officially sanctioned for use here. That clearance came just months after a surge in dengue cases – the World Health Organization logged a record 14.4 million infections worldwide in 2024, with India accounting for over 232 000 cases and more than 200 deaths.

What makes Qdenga especially appealing is its simplicity. It’s given as two 0.5 ml injections, spaced three months apart, and it works whether or not a person has been previously infected with dengue. In other words, the messy pre‑vaccination screening that plagued earlier candidates is no longer required.

Dr Reddy’s says it will handle everything from marketing to supply‑chain logistics, leveraging its extensive network of pharmacies and hospitals. The company’s CEO hinted that the rollout will be phased – starting with major urban centres before reaching smaller towns and rural districts.

Public health experts have welcomed the news, noting that a widely available vaccine could blunt the seasonal spikes that traditionally overwhelm hospitals during the monsoon months. Still, they caution that vaccination alone won’t erase dengue; vector control and community awareness remain critical.

So, while the first doses of Qdenga are expected on shelves in early 2027, the real test will be how quickly the Indian health system can vaccinate at‑risk populations and, ultimately, curb the disease’s toll.